Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age

► Safety and immunogenicity study on an affordable killed, bivalent whole-cell, cholera vaccine, Shanchol conducted prior to initiating a feasibility study in Bangladesh. ► Vaccine was safe and no adverse events elicited. ► Vaccine can be administered easily in a field settings. ► Vaccine is immunogenic in vibriocidal response in adults and in children. ► This vaccine can be used as potential tool for public health decision makers in the protection of cholera in endemic and epidemic settings.